Study | Reason for exclusion |
---|---|
Adler 1999 | Allocation: randomised. Participants: people with non‐organic psychosis. Interventions: vitamin E versus placebo. |
Akhondzadeh 2005 | Allocation: randomised. Participants: people with chronic schizophrenia. Interventions: risperidone plus lamotrigine versus risperidone plus placebo. |
Akhondzadeh 2007 | Allocation: randomised. Participants: people with chronic schizophrenia. Interventions: risperidone plus celecoxib versus risperidone plus placebo. |
Anwunah 1999 | Allocation: randomised. Participants: people with schizotypal personality disorder. |
Ayd 2001 | Allocation: randomised. Participants: people with schizotypal personality disorder. |
Azorin 2002 | Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus sertindole. |
Azorin 2006 | Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus sertindole. |
Bai 2005 | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus other atypicals (no placebo arm). |
Baker 2012 | Allocation: not RCT but pooled data from RCTs. |
Basson 2001 | Allocation: randomised. Participants: people with schizophrenia. Intervention: olanzapine versus haloperidol versus risperidone. |
Beasley 1996 | Allocation: randomised. Participants: people with schizophrenia. Intervention: olanzapine versus placebo versus haloperidol. |
Bondolfi 1998 | Allocation: randomised. Participants: people with resistant schizophrenia. Intervention: clozapine versus risperidone. |
Borison 1992a | Allocation: randomised. Participants: people with chronic schizophrenia. Intervention: risperidone versus haloperidol. |
Boyer 1995 | Allocation: randomised. Participants: people with negative schizophrenia. Intervention: amisulpride versus placebo. |
Brecher 1998 | Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus olanzapine. |
Cada 2004 | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone long‐acting injection versus placebo. |
Carson 2002 | Allocation: randomised. Participants: people with schizophrenia. Intervention: aripiprazole versus haloperidol versus placebo. |
Casey 2003 | Allocation: randomised. Participants: people with schizophrenia. Intervention: aripiprazole versus placebo. |
Castle 2015 | Allocation: not RCT but pooled data from RCTs. |
Chan 2007 | Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus aripiprazole. |
Chue 2002 | Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone long‐acting injection versus olanzapine. |
Ciliberto 2005 | Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone long‐acting injection versus placebo. |
Citrome 2004 | Allocation: randomised. Participants: people with schizophrenia. Intervention: antipsychotic monotherapy versus antipsychotic plus valproate. |
Claus 1992 | Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus haloperidol. |
Conley 1998 | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus olanzapine. |
Cooper 1997 | Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus olanzapine versus quetiapine. |
Cornblatt 2002 | Allocation: randomised. Participants: people with schizophrenia. Intervention: aripiprazole versus olanzapine. |
Crawford 1997 | Allocation: randomised. Participants: people with schizophrenia. Intervention: olanzapine versus haloperidol versus placebo. |
Csernansky 1999 | Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus haloperidol. |
David 2000 | Allocation: not randomised. |
Davis 2001 | Allocation: not randomised. |
Dossenbach 1997 | Allocation: randomised. Participants: people with schizophrenia. Interventions: olanzapine versus fluphenazine. |
Dubitsky 2002 | Allocation: randomised. Participants: people with schizophrenia. Intervention: aripiprazole versus risperidone. |
Edgell 2000 | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus olanzapine. |
Fleming 2007a | Allocation: randomised. Participants: people with schizophrenia. Intervention: asenapine versus risperidone versus placebo. |
Friedman 2000 | Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus haloperidol. |
Gismondi 2004 | Allocation: randomised. Participants: people with schizophrenia. Interventions: aripiprazole versus perphenazine. |
Gregor 2000 | Allocation: randomised. Participants: people with schizophrenia. Interventions: olanzapine versus haloperidol. |
Harvey 2001 | Allocation: randomised. Participants: people with schizophrenia and schizoaffective disorder. Interventions: risperidone versus olanzapine. |
Hwang 2003 | Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus amisulpride. |
Hwang 2005 | Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus aripiprazole. |
Kane 2005 | Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone, sertindole, and aripiprazole. |
Kinon 1998 | Allocation: randomised. Participants: people with schizophrenia. Interventions: olanzapine versus haloperidol. |
Kinon 2015 | Allocation: not RCT, but pooled data from five RCTs. |
Lauriello 2005 | Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone long‐acting injection versus placebo. |
Lemmens 1994 | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus zuclopenthixol dihydrochloride. |
Lieberman 2005 | Allocation: randomised. Participants: people with schizophrenia. Interventions: olanzapine versus haloperidol. |
Lindstrom 1994 | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus haloperidol. |
Loo 1997 | Allocation: randomised. Participants: people with deficit schizophrenia. Interventions: amisulpride versus placebo. |
Lopez 1996 | Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus haloperidol. |
Lopez‐Ibor 1992 | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus haloperidol. |
Luo 2011 | Allocation: randomised. Participants: people with schizophrenia. Intervention: paliperidone versus olanzapine versus placebo. |
Marder 1991 | Allocation: not RCT, but pooled data from two RCTs. |
McClellan 2009 | Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus olanzapine or molindone. |
McClure 2009 | Allocation: randomised. Patients: Schizotypal personality disorder. |
McKenna 2004 | Allocation: randomised. Participants: people with refractory schizophrenia. Intervention: clozapine versus clozapine plus risperidone. |
Nasrallah 2004a | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone long‐acting injection versus placebo. |
NCT 02109562 | Allocation: randomised.
Participants: people with schizophrenia. Interventions: resperidone injections versus placebo. |
NCT00034892 | Allocation: randomised. Participants: people with schizophrenia, schizophreniform disorder, and schizoaffective disorder. Interventions: risperidone versus quetiapine versus olanzapine. |
NCT00088075 | Allocation: randomised. Participants: adolescents with schizophrenia. |
NCT00202007 | Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus aripiprazole. |
NCT00249119 | Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone long‐acting injection versus placebo. |
NCT00253136 | Allocation: randomised. Participants: people with schizophrenia. Interventions: risperidone versus haloperidol. |
NCT00305474 | Allocation: randomised. Participants: non‐psychotic relatives of people with schizophrenia. |
Peuskens 1995 | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus haloperidol. |
Peuskens 2001 | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus amisulpride. |
Peuskens 2001a | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus amisulpride plus haloperidol. |
Pikalov 2012 | Allocation: not RCT, but pooled data from seven RCTs. |
Rabinowitz 2001 | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus haloperidol. |
Rein 2002 | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus amisulpride. |
Revicki 1996 | Allocation: randomised. Participants: people with schizophrenia. Interventions: olanzapine versus haloperidol. |
Riedel 2003 | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone plus celecoxib versus risperidone plus placebo. |
Schmechtig 2010 | Allocation: randomised. Participants: health volunteers. |
Siever 2002 | Allocation: randomised. Participants: people with schizotypal personality disorder. |
Tollefson 1996 | Allocation: randomised. Participants: people with schizophrenia. Intervention: olanzapine versus risperidone. |
Tran 1997 | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus olanzapine. |
Tsai 2004 | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone plus sarcosine versus risperidone plus placebo. |
Tsai 2006 | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone plus D‐alanine versus risperidone plus placebo. |
Urioste 2004 | Allocation: randomised. Participants: people with schizophrenia and schizoaffective disorder. Intervention: risperidone long‐acting injection versus placebo. |
Wang 2003 | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone plus valproate versus risperidone plus placebo. |
Weickert 2003 | Allocation: randomised. Participants: people with schizophrenia. Intervention: antipsychotic drugs (risperidone, olanzapine, quetiapine) versus placebo. |
Weiden 2005 | Allocation: randomised. Participants: schizophrenia with obesity. Intervention: sibutramin vs placebo |
Wirshing 1995 | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus haloperidol. |
Yamawaki 1996 | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone versus clocapramine (an atypical antipsychotic of the imidobenzyl class). |
Zhang 2002 | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone plus antioxidants versus risperidone plus placebo. |
Zhong 2006 | Allocation: randomised. Participants: people with schizophrenia. Intervention: risperidone plus buflomedil versus risperidone plus placebo. |